CURRENTS PARTNERSHIPS

      R&D collaboration / Licensing

      Top 20 Pharma Company
      A R&D collaboration with option to license for identification and verification of therapeutic antibody candidates against TRPV1.

       

      R&D collaboration

      Oblique Therapeutics AB (publ.) and Targovax will jointly explore the feasibility and anti-cancer potential of merging their ONCOS and AbiProt® technology platforms.
      ONCOS will be used to deliver AbiProt® antibodies against hard-to-reach targets such as mutant RAS.

       

      R&D collaboration

      Collaborations with Prof. Kent Jardemark M.D Ph.D. at Translational pharmacology at the Department of Physiology and Pharmacology. Prof. Jardemark has expertise in antibody hit-to-lead screening, in vitro KRAS models, and ion-channel pharmacology.

      R&D collaboration

      Collaborations with Senior Physician Matthias Löhr M.D. PH.D.  at Department of Upper Gastroenterology, Karolinska Comprehensive Cancer Center. Clinical expertise in pancreatic cancer.

      R&D collaboration

      Collaboration with Monica Marcus – Senior Lab Manager at Translational pharmacology at the Department of Physiology and Pharmacology.

      R&D Collaboration

       

      Collaboration with Oscar Jungholm, PH.D. at Translational pharmacology at the Department of Physiology and Pharmacology